Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
Ann Hematol. 2018 Sep;97(9):1745.
doi: 10.1007/s00277-018-3403-9.
1 Department of Internal Medicine III with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Müllner-Hauptstr. 48, 5020, Salzburg, Austria.
2 Salzburg Cancer Research Institute - Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR) and Cancer Cluster Salzburg (CCS), Salzburg, Austria.
3 Division of Hematology and Oncology, Laboratory for Molecular Genetics and Diagnostics, Innsbruck Medical University, Innsbruck, Austria.
4 Centre for Hematology and Medical Oncology, Kepler University Hospital, Linz, Austria.
5 Department for Internal Medicine IV, Hospital Wels-Grieskirchen, Wels, Austria.
7 Internal Medicine I (Hemostasis, Hematology and Stem Cell Transplantation and Medical Oncology), Ordensklinikum Linz Elisabethinen, Linz, Austria.
8 Department for Internal Medicine IV, Hospital Barmherzige Schwestern Linz, Linz, Austria.
9 Department of Internal Medicine III with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Müllner-Hauptstr. 48, 5020, Salzburg, Austria. r.greil@salk.at.
10 Salzburg Cancer Research Institute - Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR) and Cancer Cluster Salzburg (CCS), Salzburg, Austria. r.greil@salk.at.
The original version of this article contained a mistake. The name of Tanja Nicole Hartman should have been Tanja Nicole Hartmann. The original article has been corrected.